$1.43
8.92% day before yesterday
Nasdaq, Jul 11, 10:08 pm CET
ISIN
US98420X1037
Symbol
XFOR
Sector
Industry

X4 Pharmaceuticals, Inc. Stock price

$1.43
-1.78 55.38% 1M
-15.53 91.57% 6M
-20.58 93.50% YTD
-19.31 93.11% 1Y
-32.47 95.78% 3Y
-239.47 99.41% 5Y
-2,523.97 99.94% 10Y
-2,523.97 99.94% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.14 8.92%
ISIN
US98420X1037
Symbol
XFOR
Sector
Industry

Key metrics

Basic
Market capitalization
$8.3m
Enterprise Value
$-3.0m
Net debt
positive
Cash
$87.0m
Shares outstanding
5.8m
Valuation (TTM | estimate)
P/E
0.7 | negative
P/S
0.3 | 0.2
EV/Sales
negative | negative
EV/FCF
0.0
P/B
0.4
Financial Health
Equity Ratio
15.1%
Return on Equity
-169.1%
ROCE
-8.2%
ROIC
-26.9%
Debt/Equity
3.3
Financials (TTM | estimate)
Revenue
$31.4m | $35.8m
EBITDA
$-7.4m | -
EBIT
$-8.6m | $-88.4m
Net Income
$14.6m | $-56.4m
Free Cash Flow
$-119.9m
Growth (TTM | estimate)
Revenue
- | 1,298.4%
EBITDA
93.6% | -
EBIT
92.6% | 37.5%
Net Income
111.3% | -50.5%
Free Cash Flow
-15.7%
Margin (TTM | estimate)
Gross
82.4%
EBITDA
-23.4% | -
EBIT
-27.3%
Net
46.5% | -157.4%
Free Cash Flow
-382.4%
More
EPS
$2.1
FCF per Share
$-20.7
Short interest
8.5%
Employees
143
Rev per Employee
$20.0k
Show more

Is X4 Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

X4 Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a X4 Pharmaceuticals, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a X4 Pharmaceuticals, Inc. forecast:

Buy
91%
Hold
9%

Financial data from X4 Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
-
100%
- Direct Costs 5.51 5.51
-
18%
26 26
-
82%
- Selling and Administrative Expenses 59 59
29% 29%
188%
- Research and Development Expense 80 80
15% 15%
256%
-7.35 -7.35
94% 94%
-23%
- Depreciation and Amortization 1.21 1.21
246% 246%
4%
EBIT (Operating Income) EBIT -8.56 -8.56
93% 93%
-27%
Net Profit 15 15
111% 111%
47%

In millions USD.

Don't miss a Thing! We will send you all news about X4 Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

X4 Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
26 days ago
Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that investigators were willing and able to reduce injectable G-CSF while maintaining ANC levels in the normal range Data continue to strengthen confidence in potential success of ongoing global, pivotal ...
Neutral
GlobeNewsWire
about one month ago
BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor, an oral CXCR4 antagonist, for the treatment of chronic neutropenia (CN). The company is currently conducting a glob...
Neutral
GlobeNewsWire
about one month ago
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 30, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan ...
More X4 Pharmaceuticals, Inc. News

Company Profile

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.

Head office United States
CEO Paula Ragan
Employees 143
Founded 2010
Website www.x4pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today